To the Editor.—
We thank Drs Mann and Kapur1 for their thoughtful and cogent treatment of the antidepressant-suicidality question. Their central neurochemical hypothesis was that fluoxetine (or any selective serotonergic reuptake blocker) might cause the presynaptic serotonergic neuron to temporarily decrease its firing rates. Such temporary serotonergic hypofunction would, in effect, leave the patient more susceptible to depression and subsequent suicidal ideation. The return of the depressive symptoms after experimental depletion of the serotonin precursor could be cited in support of this conjecture.2 However, the reemergence of original depressive symptoms or "relapse" contrasts sharply with the presentation of our patients who became suicidal during treatment with fluoxetine.We have now had experience with five such patients. All were women. None had a history of significant suicidal behavior; all described their distress as an intense and novel somaticemotional state; all reported an urge to pace that paralleled the
Wirshing WC, Putten TV, Rosenberg J, Marder S, Ames D, Hicks-Gray T. Fluoxetine, Akathisia, and Suicidality: Is There a Causal Connection? Arch Gen Psychiatry. 1992;49(7):580–581. doi:10.1001/archpsyc.1992.01820070074012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: